MANAGEMENT'S DISCUSSION AND ANALYSIS
OF THE COMPANY'S FINANCIAL CONDITION AND RESULTS OF OPERATIONS
FOR THE TWELVE MONTHS ENDED OCTOBER 31, 2012

Amended and Restated

FORM 51-102F1

Date and Subject of Report

The following Management Discussion & Analysis ("MD&A") is intended to assist in the understanding of the trends and significant changes in the financial condition and results of operations of Easymed Technologies Inc., formerly Easymed Services Inc., ("EasyMed", "Easymed", or the "Company") for the year ended October 31, 2012. This MD&A includes comparisons where possible. It should be read in conjunction with the audited annual financial statements for the year ended October 31, 2012, which can be viewed at SEDAR at www.sedar.com. The MD&A has been prepared effective February 26, 2013 and updated on November 25, 2013 when this MD&A was amended and restated.

Financial results are now being reported in accordance with International Financial Reporting Standards ("IFRS"). As a result, accounting policies, presentation, financial statement captions and terminology used in this discussion and analysis differ from those used in previous financial reporting. Further details on the transition to IFRS are included in Notes 2 and 11 of the consolidated financial statements for the twelve month period ended October 31, 2012. All financial results are reported in Swiss Francs which is the presentation currency of the Company. Additional information relating to the Company can be found on the SEDAR website at www.sedar.com.

Forward Looking Statements

Forward looking statements are statements that are not historical facts and are generally, but not always identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential", "interprets" and similar expressions, or that events or conditions "will", "may", "could" or "should" occur. The information contained herein may contain forward-looking statements including expectations of future business opportunities, cash flows or earnings. The Company is in the business of providing medical and health technology services. Readers are cautioned that the Company is a start-up company in the development stage of such services and technologies. At this time we cannot accurately predict what course of action will and can be taken with respect to these technologies. There are risks inherent in the technology companies and, as a start-up company. The Company is subject to these risks, including, but not limited the risk associated with the transition from research and development activities to commercial activities, market acceptance and adoption of products and or services, regulatory risks, risks relating to the protection of intellectual property, risks inherent in the conduct of research and development activities, potential product liability, competition and the risks posed by potential technological advances.

Forwarding looking statements are based on current expectations that involve a number of risks and uncertainties that could cause actual results to materially differ from those anticipated. While we believe the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate. These factors should be considered carefully, and readers should not place undue reliance on forward-looking statements.

The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether written or oral that may be made by, or on behalf of, the Company, except as required by applicable securities laws.

The following table outlines certain significant forward-looking statements contained in this MD&A and provides the material assumptions used to develop such forward-looking statements and material risk factors that could cause actual results to differ materially from the forward looking statements.

Forwarding looking statements	***Assumptions***	***Risk factors***
As at November 25, 2013, the Company is discussing contracts with medical service provider in United Kingdom and USA. The Company expects to close additional contracts during near future.	*Based on the progress with the negotiation with potential customers, management believes more contracts can be closed in the near future*	*Change in market condition, availability of similar products offered by competitor.*
The Company intends to fund the Company's operation in the future with debt and equity financing.	*Based on the past history of the Company, the Company was able to raise funds when needed through either private placement or debt financing*	*Change in interest rate, support by related parties, change in condition of capital market*

Description of Business and Review

EasyMed was incorporated on May 2, 2005 under Swiss law. The Company is a medical and health technology services company based on an internet and mobile phone platform offering a range of services and applications for individuals, families, medical and health care professionals, pharmaceutical manufacturers and insurance companies. On February 12, 2010, the Company was acquired by InCana Investments Inc. ("InCana"), a publically traded Canadian company listed on the Canadian National Stock Exchange ("CNSX"). The business combination between InCana and EasyMed was accounted for as a reverse take-over as the former shareholders of EasyMed acquired effective control of the combined companies. On February 16, 2010, InCana's name was changed from InCana Investments Inc. to EasyMed Services Inc., which was subsequently changed to Easymed Technologies Inc. on October 18, 2013. The shares of EasyMed are traded under the ticker symbol EZM on the CNSX.

Overall Performance

Overall Market Trend

The main service features provided by the Company include medical and health reminders, on-line and mobile phone access and interactivity, telemedicine, and an international medical and health information service and its life science portal. The company is headquartered in Geneva, Switzerland with the corporate registered office in 1110-925 West Georgia St. Vancouver, BC. The Company also has offices in Chennai, India and Toronto, Canada.

The global healthcare market continues its trend towards digitization of medical records and increased connectivity both within and between medical institutions. For an example, the USA government has an initiative to encourage health care providers to adopt an electronic health record system. More information about this initiative is available at *http://www.healthit.gov/providers-professionals*.

The Company's Products

During the year ended October 31, 2012, the development of EasyMeds' two major products, International Medical Passport and Easy SmartCare were significantly completed.

International Medical Passport ("IMP")

EasyMed's International Medical Passport makes medical records accessible worldwide by smartphone. The International Medical Passport puts the complete record on a smartphone together with instant access to pre-approved doctors, clinics and hospitals around the world. The Medical Passport works on all phone, PDA and web platforms and operates in over 80 countries with 300+ mobile carriers. Cloud-based, secure, compliant and accessible on iPhone, Android, Windows and Blackberry platforms, EasyMed's International Medical Passport meets HIPAA requirements, supports HL-7 (the global authority on standards for interoperability of health information technology) and is IBM-certified.

During the year ended October 31, 2012, the Company tested trial run of IMP with various large companies including Comedie-Francaise, Nexter Group. Subsequent to the year ended October 31, 2012, the Company also signed a contract with Chanel Group to trail the IMP in January 2013. The costs of conducting these trials were incurred by the user companies.

These trial contracts are still in effect but uptake of the IMP has not been as extensive as was hoped. Easymed's partner, TravelSante, was responsible for marketing the IMP to its clients for trials and has been unable to convert at levels expected. The company plans to follow up with its trial partners to see if the trials should be continued or if it should be closed.

On February 25, 2013, the Company further enhances IMP by releasing an application software available on all of Apple's iphone, ipad, and internet-ready ipod touch.

Easy SmartCare ("ES")

Easy SmartCare is a software product that allows clinics, hospitals and doctors' practices to communicate with patients through text messages/PUSH notifications on their smartphones and other mobile devices. Easy SmartCare reduces missed appointments, improves preparation, sends medication reminders and improves overall outpatient management.

On October 16, 2012, the Company reported the result of a study conducted by the University of Geneva in connection with a trial with 5,076 patients to compare the impact of text message appointment reminders versus phone call reminders in an academic primary care clinic. The Company's ES was used to send the automated text message reminders for the trial and the trial was conducted during a six months period from November 2010 to April 2011. The trial result shows the use of ES significantly reduce the rate of miss appointment with cost saving. The costs of conducting these trials were incurred by the user companies.

Research and Development Cost

The company's research and development costs in connection with the ES and MIP were mainly comprised of fees paid to IT consultants for the development of the Company's ES and MIP. Material costs are insignificant. As these IT consultants work on both products, it is unrealistic to divide their fees accurately among MIP and ES. The consulting fees incurred during fiscal 2012 and 2011 in connection with research and development are CHF 361,809 and CHF 27,246 respectively.

Outlook

As at November 25, 2013, the date when this MD&A amended and restated, the company has not carried out significant commercial operations and has yet to achieve profitability. The Company has finished significantly finished its product development. In fiscal 2013, the Company's main focus are commercializing of ES and IMP in both USA and Europe

In order to enhance the marketing of the Company's products, the Company signs a non-exclusive cooperation and commission agreement with a Swiss-based sales company GKAN Holdings SA ("GKAN") for distribution of Easymed's IMP and ES on February 4, 2013. Under the terms of the agreement, GKAN will seek out and jointly market customers for IMP and ES in Europe, USA, and China.

Subsequent to the year ended October 31, 2012, the Company entered into a service agreement with the Department of Cardiology of the University Hospital of Geneva on July 4, 2013, for the use of the Company's Easy SmartCare. The Company started to deliver the services commencing September 1, 2013. The term of this agreement is indefinite but subject for review annually. The next review date is July 1, 2014. The monthly revenue in connection with this service agreement is CHF2,000.

As at November 25, 2013, the Company is discussing contracts with medical service provider in United Kingdom and USA. The Company expects to close additional contracts during near future.

The Company realized that the existing sources on hands are not adequate to support the Company to reach its long term business goal. The Company continues to pursue funding opportunities with the aim a raising investment capital the fund its operations and ongoing product development and maintenance.

Subsequent to the year ended October 31, 2012, the Company consolidated its common shares at a ratio of 5 old shares for one new share, changed its name to Easymed Technologies Inc., and registered office address to 1110-925 West Georgia St., Vancouver, BC on October 18, 2013. As a result, the number of outstanding shares, loss per share, number of share purchase warrants and options outstanding presented in this MD&A have been adjusted to reflect the effect of this 5-1 share consolidation, unless otherwise stated.

Subsequent to the year ended October 31, 2012, the Company closed a private placement on December 20, 2012 for the issuance of 294,118 (post 5-1 share consolidation) common shares and share purchase warrants for gross proceeds of CHF1,155,375. The Company has used the proceeds to pay down various related party loan that would otherwise be due in the fiscal 2013 with the aim of improving the Company's working capital. The Company has a history of funding its past operations through either equity or debt financing. However there is no guarantee that the Company can do this in the future.

Selected Annual Information
The following table summarizes the results of operations for the eight most recent quarters and is derived from the Company's financial statements. These sums are being reported in Swiss Francs and did not change as a result of the adoption of policies concerning financial instruments.

	31-Oct 2012 (IFRS)	31-Oct 2011 (IFRS)	31-Oct 2010 (IFRS)
Expenses	1,279,272	1,092,382	935,635
Net loss	(1,277,796)	(1,085,461)	(933,922)
Other income	1,476	6,921	1,713
Total assets	22,866	31,408	113,499
Total long-term liabilities	251,821	515,168	-
Net loss per share and diluted loss per share (i)	(0.21)	(0.18)	(0.22)

(i) Loss per share has been amended to reflect the 5-1 share consolidation came effective October 18, 2013

The Company is a start-up company which has not earned significantly revenue from its operations since inception. Even though the Company is actively conducting its sales activities in fiscal 2013 and expect to finalize various sales contract in 2013, it is difficult to predict when will the Company start to materialize significant sales contracts and start to earn significant revenue from its operations.

As the development of ES and IMP was significantly completed in fiscal 2012, the Company does not expect to incur significantly consulting fees in the development of these products. Depends on the terms of the Company's sales contract, selling expenses may increase in fiscal 2013 when the Company's sales contract start to materialize.

As the Company has only limited financial resources on hand, the Company will curtail its operations (except the efforts in making sales) in 2013. As a result, management expects its operating expenses will decrease until at a point the Company starts to earn revenues from its operation.

Selected Quarterly Information

The following table summarizes the results of operations for the eight most recent quarters and is derived from the Company's financial statements. The Company is in the process of developing an internet and mobile phone platform for providing services and application for individuals and medical professionals. As a result, the Company has not earned operating revenue since inception. Its losses incurred in the recent eight quarters was mainly a result of incurring expenses for the development of the internal and mobile phone platform, day-to-day administrative and managerial expenditures, plus non-recurring expenses such as stock based compensation recorded to account for vesting of options issued to management and consultants. As a result, the Company's losses in the past, as well as in the near future, are not subject to seasonality. The fluctuation within the past eight quarters were mainly driven by incidental events such as the vesting of options granted from time to time. Losses in 2011 Q4 (CHF 427,044) and 2012 Q1 (CHF 454,924) are higher as 1,200,000 options were granted in late 2011 Q3. Stock-based compensation of CHF 195,363 and CHF 213,790 were recorded to these two quarters respectively. Losses in 2011 Q1 was also higher than average as the Company incurred CHF 218,269 salaries and consultant fee in that quarter which is higher than the average to account for a non-recurring consulting fees paid for mobile platform development work done in that quarter.

	Q4 2012 (CHF)	Q3 2012 (CHF)	Q2 2012 (CHF)	Q1 2012 (CHF)
Expenses	248,720	281,444	279,888	469,220
Net loss	(241,418)	(284,087)	(297,367)	(454,924)
Total assets	22,866	72,498	34,311	6,527
Total long-term liabilities	227,984	971,142	815,910	967,488
Loss per share, basic and diluted (i)	(0.15)	(0.05)	(0.05)	(0.10)

	Q4 2011 (CHF)	Q3 2011 (CHF)	Q2 2011 (CHF)	Q1 2011 (CHF)
Expenses	418,977	162,652	189,679	321,080
Net loss	(427,044)	(147,658)	(189,679)	(321,080)
Total assets	31,408	30,023	26,540	118,640
Total long-term liabilities	209,068	620,295	487,005	136,243
Loss per share, basic and diluted (i)	(0.10)	(0.05)	(0.05)	(0.05)

(i) Loss per share has been amended to reflect the 5-1 share consolidation came effective October 18, 2013

Results of the Year Ended October 31, 2012

Loss in 2012 was CHF 1,277,796 comparing to a loss of CHF 1,085,461 in 2011, an increase of CHF 192,335. The CHF 1,277,796 loss in 2012 was mainly a result of incurring operating expenses of CHF 1,279,272 (2011 – CHF 1,092,383). Other income, ancillary income generated from Life Science Portal services, was CHF 1,476 in 2012 compared to CHF 6,921 in 2011. Operating expenses in 2012 and 2011 are broken down as follows:

		2012	2011	2012-2011
		CHF	CHF	CHF
1	Salaries, management consulting	**369,413**	**576,345**	**(206,932)**
2	Stock-based compensation	**328,296**	**209,672**	**118,623**
3	General operating expenses:			
3.1	IT consulting and others	361,809	27,246	334,563
3.2	Travel	19,738	76,831	(57,093)
3.3	Finance charges and interest	69,880	27,983	41,898
3.4	Utilities	14,797	10,209	4,558
3.5	Promotion and advertisement	7,891	36,749	(28,858)
3.6	Office and administration	88,532	111,198	(22,666)
	Total general operating expenses	**562,647**	**290,216**	**272,402**
4	Interest, convertible debenture interest	**18,916**	**16,149**	**2,767**
	Total Operating expenses (1+2+3+4)	**1,279,272**	**1,092,382**	**186,860**

1 and 3.1 –Salaries and management consulting plus IT and other consulting totaled CHF 731,222 in 2012 compared to CHF 603,591 in 2011, a CHF 127,631 increase. This increase if a result of more business activities conducted during 2012 in order to develop and advance the Company's business. Salaries and management consulting represented charges in connection to management services rendered by consultants and salaries paid to the Company's officers. IT consultant and others fees represented charges in connection mainly with services provided for the development the Company's internet and mobile phone platform of delivering the Company's services and other miscellaneous consulting services like strategic planning.

2 – Stock-based compensation increased in 2012 as the Company granted 50,000 (or 250,000 pre 5-1 share consolidation) options in 2012 and the 240,000 (or 1,200,000 pre 5-1 share consolidation) options granted in late 2011 were mostly vested in the fiscal 2012.

3.2 – Travel decreased in 2012 as there were travelling expenses in connection with various trade conferences incurred in 2011. No similar travelling expenses were incurred in 2012

3.3 – Finance charges and interest expenses increased as the amount of outstanding loans (including related party loans) increased from CHF 526,100 in 2011 to CHF 1,220,506 as at October 31, 2012, an increase of CHF 694,406.

4. – Interest in connection with convertible debenture increased slightly by CHF 2,767 as the carrying value of the outstanding convertible debenture increased from CHF209,068 in 2011 to CHF227,984 in 2012.

Three Months Ended October 31, 2012 ("2012 Q4")

Loss for 2012 Q4 was CHF 241,418 comparing to the CHF 427,044 loss incurred in the same quarter of 2011, a decrease of CHF 185,626. The CHF 241,418 loss in the 2012 Q4 was mainly a result of incurring operating expenses of CHF 248,720 (2012 Q4 – CHF 418,977). Operating expenses in 2012 and 2011 Q4 are broken down as follows:

		2012 Q4	2011 Q4	2012-2011 Q4
		CHF	CHF	CHF
1	Salaries, management consulting	**109,305**	**249,924**	**(140,619)**
2	Stock-based compensation	**15,151**	**195,363**	**(180,212)**
3	General operating expenses:			
3.1	IT consulting and others	67,104	(148,612)	215,716
3.2	Finance charges and interest	22,553	26,730	(4,177)
3.3	Utilities	3,727	7,428	(3,701)
3.4	Promotion and advertisement	207	36,749	(36,542)
3.5	Travel	183	15,409	(15,226)
3.6	Office and administration	25,735	31,853	(6,118)
	Total general operating expenses	**119,509**	**(30,443)**	**149,952**
4	Interest, convertible debenture	**4,755**	**4,127**	**628**
	Total operating expenses (1+2+3+4)	**248,720**	**418,971**	**(170,251)**

1 and 3.1 – Salaries and management consulting plus IT and other consulting were totaling CHF 176,409 in 2012 Q4 comparing to CHF 101,312 in 2011 Q4, a CHF 75,097 increase. This increase if a result of more business activities conducted during 2012 in order to develop and advance the Company's business.

2 – Stock-based compensation decreased in 2012 Q4 as the Company did not granted options in 2012 Q4 and the 240,000 options (or 1,200,000 pre 5-1 share consolidation) granted in late 2011 had been mostly vested before 2012 Q4.

3.4 – Advertisement decreased in 2012 Q4 as less promotional activities performed in 2012 Q4

3.5 – Travel decreased in 2012 as there were travelling expenses in connection with various trade conferences incurred in 2011. No similar travelling expenses were incurred in 2012

As discussed in the "Selected Quarterly Information" section, the Company's quarterly result was not subject to seasonality and is more affected by the amount of on-going events like the development work in connection with the Company's internet and mobile phone platform, and non-recurring events such as vesting of stock-based compensation

Liquidity and Capital Resources

As at October 31, 2012, the Company had cash CHF 16,770 (October 31, 2011 – CHF 27,604) and working capital deficiency of CHF 1,413,307 (October 31, 2011 – deficiency of CHF 247,535. As discussed in the section "Outlook", the Company completed a private placement in 2013 Q1 to raise CHF1,155,375 to repay various related party loan that would due in fiscal 2013 in order to reduce the working capital deficiency.

Many of the related party loans as at October 31, 2012 were due or have the due dates extended by creditors when the private placement was closed. It was agreed by management that in order to keep a good relationship with the company's creditor and to not risk default, funds needed to be raised to repay these outstanding loans.

Net cash used in operating activities during the twelve months ended October 31, 2012 was CHF 752,315 (2011 – CHF 805,039). The cash used in operating activities for the current year consists primarily of salaries and consulting fees and general operating expenses of CHF 932,060 (2011 – CHF 867,117).

Net cash provided by financing activities during the twelve months ended October 31, 2012 was CHF 740,986 (2011 – CHF 720,331). The cash from financing activity for the current year was due to a loan from a related party.

Management realized that the current resources on hand are not adequate to meet the operation needs in the next twelve operating periods and to meet its long term business goal. The Company used CHF 752,315 and CHF 805,039 cash for its operating activities in fiscal 2012 and 2011 respectively. The projected cash requirement in each future quarter is approximately CHF 195,000 based on these historical data. The Company intends to fund the Company's operation in the future with debt and equity financing. Management will closely monitor the Company's working capital and may slow down its development work with respect to its internet/mobile phone platform in order to preserve cash if needed.

Related Party Transactions

During the year ended October 31, 2012 the Company incurred CHF $191,760 (2011 – CHF 233,181) in consulting and management fees to directors and officers included in salaries and consultants. Details as follows:

	2012	2011
	CHF	CHF
Carmelo Bisognano (director and COO)	84,000	82,020
Thomas Wacinski (director and CTO)	72,000	76,690
Jared Scharf (director and CFO)	35,760	74,471
	191,760	233,181

In addition, stock-based compensation vested by directors and officers were CHF 328,296 and CHF 209,672 in fiscal 2012 and 2011 respectively.

The amounts charged to the Company for the services provided have been determined by negotiation among the parties and, in certain cases, are covered by signed agreements. These transactions were in the normal course of operations and were measured at the exchange value, which represented the amount of consideration established and agreed to by the related parties.

As at October 31, 2012, the Company had the following related party loans outstanding lent by Ayub Khan, a significant creditor that financed most of the Company's operations in 2012:

a) A loan for CHF 120,000 (2011 – 120,000) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures October 2012. The loan is repayable with accrued interest at anytime during the term of the loan if EasyMed Services Inc. completes a private placement for a minimum of US $1,000,000. The early repayment on the close of the private placement is at the option of the lender.
b) A loan for CHF 100,000 (2011 – 100,000) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures June 2013. c) A loan for CHF 40,000 (2011 – 40,000) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures October 2013.
c) A loan for CHF 40,000 (2011 – 40,000) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures October 2013.
d) A loan for CHF 6,600 (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matured March 2012.
e) A loan for CHF 40,000 (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures December 2013.
f) A loan for CHF 50,000 (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures December 2013.
g) A loan for CHF 50,000 (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures January 2014.
h) A loan for CHF 70,000 (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures February 2014.
i) A loan for CHF 73,000 (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures March 2014.
j) A loan for CHF 80,000 (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures April 2014.
k) A loan for CHF 75,000 (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures July 2014.
l) A loan for CHF 46,706 (US $50,000) (2011 – US $50,000) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures July 2013.
m) A loan for CHF 112,093 (US $120,000) (2011 – US $120,000l) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures Sep 2013.
n) A loan for CHF 23,353(US $25,000) (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures September 2013.
o) A loan for CHF 16,184 (US $18,000) (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures November 2013.
p) A loan for CHF 23,353 (US $25,000) (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures October 2014.
q) A loan for CHF 23,353 (US $25,000) (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures October 2014.
r) A loan for CHF 19,610 (CAD$20,000) (2011 – Nil) bearing interest at 5% per annum payable at the maturity of the loan. The loan matures April 2014.
s) A loan for CHF 101,765 (CAD $108,000) (2011 – nil) bearing an interest at 5% per annum payable at the maturity of the loan. The loan matures June 2014.
t) A loan for CHF 19,610 (CAD $20,000) (2011 – Nil) bearing an interest at 5% per annum payable at the maturity of the loan. The loan matures June 2014.

u) A loan for CHF 6,042 (Euro 5,000) (2011 – Nil) bearing an interest at 5% per annum payable at the maturity of the loan (December 2013)

Capital Stock, Option, and Warrant

Capital Stock

On December 20, 2012, the Company completed a non-brokered private placement of 294,118 units (or 1,470,588 pre 5-1 share consolidation units) for Cdn$ $4.25 per unit (or Cdn$0.85/ pre 5-1 share consolidation unit) for gross proceeds of CHF1,155,375. Each unit consisted of one common share and one common share purchase warrant which holds a period of two years and has an exercise price of Cdn$6.00 (post 5-1 share consolidation). The proceeds from the placement were used to settle CHF1,155,375 of related party loans outstanding.

	Number of share/Pre 5-1 share consolidation	Number of share/Post 5-1 share consolidation
EasyMed Services SA share balance, October 31, 2011	30,345,872	6,069,174
Exercise of warrants	750,000	150,000
Issued common shares at October 31, 2012	31,095,872	6,219,174
Issued common shares for private placement	1,470,588	294,118
Issued common shares at November 25, 2013	32,566,460	6,513,292

As at November 25, 2013, the date when this MD&A was amended and restated, the Company had 6,513,392 common shares issued and outstanding.

Warrants

Subsequent to the year ended October 31, 2012, a total of 294,118 warrants (post 5-1 share consolidation) were granted in connection with the December 20, 2012 private placement. Continuity is as follows:

	Number of Warrants (pre 5-1 consolidation)	Number of Warrants (post 5-1 consolidation)
Outstanding warrants, October 31, 2010	1,500,000	300,000
Exercised	(750,000)	(150,000)
Outstanding warrants, October 31, 2011	750,000	150,000
Exercised	(750,000)	(150,000)
December 20, 2012 issuance	1,470,588	294,118
Outstanding warrants, November 25, 2013	1,470,588	294,118

As at November 25, 2013, the date when this MD&A was amended and restated, the Company had 294,118 warrants outstanding that can be converted into common shares of the Company on one-to-one basis.

Options

Under the Company's stock option plan, the board of directors may grant options for the purchase of up to 10% of the total number of issued and outstanding common shares of the Company. Options granted under the plan vest over time at the discretion of the board of directors and expire no later than five years from the date of issuance. Exercise prices on options granted under the plan cannot be lower than the market price of one share on the last trading day immediately preceding the day on which the option is granted, less the maximum applicable discount permitted by CNSX Exchange.

As at November 25, 2013, the date when this MD&A was amended and restated, the Company had 290,000 options (or 1,450,000 pre 5-1 share consolidation) outstanding that can be converted into the Company's share on a one-to-one basis which is unchanged from the year ended October 31, 2012. Details are as follows:

	Number of Options (post 5-1 share consolidation)	Exercise Price of Options (post 5-1 share consolidation	Expiry Date
Stock options	190,000	CDN$7.50	May 24, 2016
Stock options	50,000	CDN$7.50	October 17, 2016
Stock options	50,000	CDN$7.50	November 1, 2016
	290,000		

Debt

The Company has received the following loans from two individual shareholders (both have less than 10% holding) of the Company:

a) Convertible debenture

On November 5, 2010, the Company borrowed CHF 250,000 in the form of a convertible debenture bearing interest at 5% per annum from an individual shareholder George Koukis. An equity component of CHF 57,081 has been recorded in shareholders' equity. Each CHF 1,000 of principal outstanding is convertible into 901 common shares of the Company. If the Company closes a private placement of at least US$3,000,000 the debenture is required to be repaid immediately.

As at October 31, 2012, the carrying amount of this convertible debenture was CHF 227,984 (2011/10/31 – CHF 209,068)

b) Unsecured loan

On February 18, 2011, the Company borrowed CHF 100,000 in the form of unsecured loan bearing interest at 10% per annum payable in one year or on the closing of a private placement of at least US$3,000,000. The lender has agreed to extend the term of the loan indefinitely with interest being accrued in accordance with the original terms. As at October 31, 2012, the carrying amount of this un-secured loan was CHF 100,000 (2011/10/31 – CHF 100,000)

In October 2012, the Company borrowed USD 25,000 from an individual shareholder, Vinod Harjani, in the form of an unsecured loan bearing interest at 5% per annum payable in October 2014. As at October 31, 2012, the carrying amount of this un-secured loan was CHF 23,837 (2011/10/31 CHF Nil)

Financial Instruments

The Company is exposed to a number of different financial risks from the normal course of business as well as the use of financial instruments. These risks are as follows:

Credit Risk
Credit risk is the loss associated with a counterparty's inability to fulfill its payment obligations. As at October 31, 2012, there was no material outstanding accounts receivable balance, and therefore the Company's credit risk is considered minimal.

Liquidity Risk
The Company's approach to managing liquidity risk is to closely monitor its liquidity position on a regular basis to ensure the Company has sufficient capital to meet its liabilities when due. As at October 31, 2012, the Company had a current asset balance of CHF 22,886 and current liabilities of CHF 1,436,193. The Company intends to fund these liabilities through the use of existing cash resources and through the issuance of common stock and loans from related parties over the coming year.

Market Risk
The Company's functional currency of the principal operational entity is CHF. Management believes the Company is not subject to material risk from fluctuations in foreign currency exchange rates.

As at October 31, 2012, the carrying value of the Company's financial instruments approximate their fair value. The carrying value of the Company's financial instruments is classified into the following categories:

	October 31, 2012	**October 31, 2011**	**October 31, 2010**
Held-for-trading	**16,770**	**27,604**	**112,103**
Receivables	**6,116**	**3,804**	**136,243**
Other financial liabilities	**1,688,014**	**794,111**	**16,243**

The fair value of the Company's accounts receivable, accounts payable and accrued liabilities, loans payable to related parties, long-term loans payable to related parties and convertible debentures approximate carrying value, which is the amount recorded on the balance sheet. The Company's other financial instrument, cash, under the fair value hierarchy is based on level one quoted prices in active markets for identical assets or liabilities.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Conversion to IFRS

The accounting policies stated in Note 3 of the financial statements for the period ended October 31, 2012 have been applied in preparing the consolidated financial statements for the period ended October 31, 2012 and 2011, the consolidated financial statements for the year ended October 31, 2011 and the opening IFRS statement of financial position on November 1, 2010, the "Transition Date". After a review of the Company's operations and accounts up to November 1, 2010, and January 31, 2011 no IFRS transitional differences were noted and therefore no reconciliations have been performed.

In preparing the financial statements comparative October 31, 2011, the Company has adjusted amounts reported previously in financial statements that were prepared in accordance with GAAP. The guidance for the first time adoption of IFRS is set out in IFRS 1. IFRS 1 provides for certain mandatory exceptions and optional exemptions for first time adopters of IFRS. The Company elected to take the following IFRS 1 optional exemptions:

IAS 21 requires translation differences arising on translation of foreign operations to be accumulated in a Separate reserve within equity. Applying these requirements retrospectively would require an entity to determine the cumulative translation differences at the transition date and separately classify these within equity. A 1st-time adopter has the option not to comply with this requirement and reset cumulative translation differences to zero at the transition date. EasyMed has elected to use this exemption.

There are no significant differences between IFRS and Canadian GAAP in connection with the Company's statements of comprehensive loss or cash flows for the period ended October 31, 2011 or the year ended October 31, 2011.

a) Stock based compensation

Under Canadian GAAP the company booked stock-based compensation related to stock options granted on a straight line basis based on the values determined by the Black-Scholes model. Under IFRS the Company must use a graded vesting schedule to record the associated stock-based compensation expense therefore there was an increase to both stock-based compensation expense and contributed surplus.

b) The effects of changes in foreign exchange rates

Under Canadian GAAP the Canadian corporation's financial statements were translated using the temporal method of translation into the Swiss franc for presentation purposes. Under IFRS, the translation method used is the current rate method which results in a cumulative translation adjustment being incurred.

Officers and Directors

Tejinder Sahota – President & CEO
Jared Scharf – CFO &Director
Thomas Wacinski - CTO & Director (Resigned on May 31, 2013)
Carmelo Bisognano - COO & Director (Resigned in September 2013)
Frank Christ – Director
Dr Thomas Aretz – Director (Resigned on February 28, 2013)
Dr Christian Lovis – Director (Resigned on February 28, 2013)